Benefits persisted despite known side effects, spreading across daily life
At the intersection of medicine and lived experience, new findings from the FLOW trial remind us that healing is not only measured in laboratory values and survival curves, but in whether a person can walk to the store, care for themselves, and inhabit their days with some degree of wholeness. Presented at the 63rd ERA Congress, the data show that semaglutide — already known to reduce kidney disease events and mortality in people with type 2 diabetes and chronic kidney disease — also meaningfully preserved quality of life, translating to roughly eight additional days per year spent in full health. In a world where over 850 million people carry the weight of chronic kidney disease, this distinction between living longer and living better is not a footnote — it is the story itself.
- For millions managing both type 2 diabetes and chronic kidney disease, daily life is a slow erosion — symptoms compound, physical capacity shrinks, and the body becomes a site of constant negotiation.
- The FLOW trial's new quality-of-life analysis raised an urgent question: could a drug that extends life also restore the texture of it, or would its gastrointestinal side effects quietly cancel any gains?
- Across 3,533 participants over two years, those receiving semaglutide held their ground — mobility, self-care, activity, and pain all improved significantly — while placebo recipients steadily declined.
- The benefits proved stubbornly consistent across age groups, body weights, kidney function levels, and cardiac histories, suggesting the effect is broad rather than confined to a fortunate few.
- Researchers and clinicians are now being pushed toward a harder conversation: treatment goals must expand beyond clinical endpoints to include how patients actually feel and function in their own lives.
At the 63rd ERA Congress, researchers presented a new dimension of the FLOW trial — a large study that had already demonstrated semaglutide reduced major kidney disease events by nearly a quarter and cut mortality risk by a fifth in people with type 2 diabetes and chronic kidney disease. The new analysis asked a quieter but equally urgent question: did the drug make people feel better?
The answer, drawn from 3,533 participants tracked over two years using the EQ-5D-5L quality-of-life questionnaire, was clear. Those receiving the once-weekly injection maintained stable scores across mobility, self-care, usual activities, and pain, while those on placebo declined. Converted into human terms, the difference amounted to roughly eight additional days per year lived in full health.
What surprised the research team, led by Professor Johannes Mann, was the breadth of the effect. Semaglutide belongs to a drug class known for gastrointestinal side effects — nausea, vomiting, constipation — and researchers had worried these might erode any quality-of-life benefit. Instead, improvements persisted across four of five measured domains and held steady across diverse patient subgroups. Only anxiety and depression showed no meaningful difference between groups.
The findings carry weight beyond the clinical. Living with two serious chronic conditions is grinding in ways that laboratory values do not capture. Patient groups, Mann noted, consistently rank quality of life alongside survival when describing what matters most to them. The FLOW data suggest semaglutide delivers on both counts — and in doing so, it challenges clinicians to expand the conversation: not only how long a treatment might extend life, but how fully it allows a person to live it.
Researchers now aim to identify the specific mechanisms behind these quality-of-life gains, a pursuit that could reshape how future treatments are developed and how the field defines what it means to heal.
At the 63rd ERA Congress, researchers presented findings that reframed how we should think about treating people with both type 2 diabetes and chronic kidney disease. The data came from the FLOW trial, a large study that had already shown semaglutide—a once-weekly injection—reduced major kidney disease events by nearly a quarter and cut the risk of death by a fifth. But the new analysis revealed something equally important: the drug made people feel better in their daily lives, equivalent to gaining roughly eight extra days per year of full health.
This matters because living with both conditions is grinding. Symptoms pile up. Medications accumulate. The body weakens. Physical capacity shrinks. For millions of people worldwide—over 850 million have chronic kidney disease, a number that has more than doubled since 1990—these aren't abstract concerns. They shape whether you can walk to the store, care for yourself, do the things that make life feel like yours.
The FLOW trial enrolled 3,533 people. Half received semaglutide; half received placebo. Researchers tracked their quality of life using a detailed questionnaire called the EQ-5D-5L, which asks people to rate their mobility, self-care, ability to do usual activities, pain levels, anxiety, and overall health perception. After two years, something clear emerged: those on semaglutide maintained stable quality-of-life scores while those on placebo declined. The difference was measurable and statistically significant. When researchers converted this into everyday terms, it translated to about eight additional days annually spent in full health.
Four of the five domains improved notably with semaglutide—mobility, self-care, usual activities, and pain or discomfort all showed significant gains compared to placebo. Only anxiety and depression showed no meaningful difference between groups. Self-rated general health, measured on a visual scale, also improved with the drug while worsening in the placebo group. These benefits held steady across different patient populations: older and younger people, those with different body weights, varying degrees of kidney function, and even those with prior heart events.
What surprised the research team, led by Professor Johannes Mann, was the breadth of improvement. Semaglutide is a GLP-1 receptor agonist, a class of drugs known for gastrointestinal side effects—nausea, vomiting, constipation. Researchers had worried these downsides might cancel out any quality-of-life gains. Instead, the benefits persisted and spread across multiple dimensions of daily living. Mann noted that when patient groups discuss what matters most, they consistently rank quality of life alongside survival itself. The findings suggest that semaglutide delivers on both fronts.
This shifts the conversation between doctors and patients. Treatment goals have traditionally centered on clinical measures—kidney function numbers, mortality rates, disease progression. Those remain crucial. But the FLOW data indicate that clinicians should also discuss how a medication will affect how patients actually feel and function. For someone managing two serious chronic conditions, that distinction can be the difference between accepting a treatment and resisting it.
The next frontier is understanding why these improvements occur. Researchers want to identify the specific mechanisms driving the quality-of-life gains and whether they operate independently from the drug's effects on kidney disease and mortality. That knowledge could reshape how other treatments are developed and evaluated, pushing the field toward a more complete picture of what healing means.
Citações Notáveis
We were surprised by the extent of the quality-of-life benefits seen with semaglutide, because they were not only clinically meaningful but consistently experienced across multiple aspects of daily life.— Professor Johannes Mann, lead author
Patients often place considerable importance on quality of life alongside longevity, and our findings reinforce the importance of a broader, patient-centered approach to treatment goals.— Professor Johannes Mann
A Conversa do Hearth Outra perspectiva sobre a história
Why does quality of life matter so much in a kidney disease trial? Isn't survival the point?
Survival is the foundation, yes. But if you're alive but can barely move, or you're in constant pain, or you can't care for yourself—that's not the full picture of health. For people living with two serious conditions, how they feel day-to-day shapes whether they'll actually take the medication, whether they'll stick with it, whether life feels worth living.
The study found improvements in mobility and self-care but not in anxiety or depression. Why the difference?
That's honest data. Semaglutide appears to work through physical mechanisms—reducing inflammation, improving kidney function, reducing the burden of disease on the body. Anxiety and depression are more complex; they're shaped by circumstance, psychology, identity. A drug can ease your physical suffering without necessarily touching the existential weight of chronic illness.
Gastrointestinal side effects are common with this drug class. How did people tolerate it if they were getting sick?
That's the surprising part. The side effects didn't erase the benefits. It's possible people adapted over time, or the improvements in how they felt overall outweighed the nausea. Or both things were true simultaneously—some discomfort, but enough gain to make it worthwhile.
Who benefits most from this? Are there patient groups where it works better?
The data showed benefits were consistent across age groups, body weights, kidney function levels, and even among people with prior heart disease. That's unusual. It suggests this isn't a drug that works brilliantly for one narrow slice of patients. It works broadly.
What happens next in the research?
They need to understand the mechanism. Why does semaglutide improve mobility and self-care? Is it weight loss? Reduced inflammation? Better kidney function feeding back into overall energy and capacity? Once they know, they can design better treatments and know which patients to prioritize.